Charles Schwab Investment Management Inc. Grows Stock Position in MediWound Ltd. $MDWD

Charles Schwab Investment Management Inc. grew its position in MediWound Ltd. (NASDAQ:MDWD) by 17.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,468 shares of the biopharmaceutical company’s stock after acquiring an additional 3,343 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.21% of MediWound worth $349,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in MDWD. Yelin Lapidot Holdings Management Ltd. lifted its position in MediWound by 0.8% during the first quarter. Yelin Lapidot Holdings Management Ltd. now owns 858,000 shares of the biopharmaceutical company’s stock worth $13,316,000 after buying an additional 6,639 shares in the last quarter. Northern Trust Corp lifted its position in MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock worth $2,577,000 after buying an additional 70,367 shares in the last quarter. ARK Investment Management LLC lifted its position in MediWound by 6.7% during the first quarter. ARK Investment Management LLC now owns 106,930 shares of the biopharmaceutical company’s stock worth $1,660,000 after buying an additional 6,684 shares in the last quarter. Silverberg Bernstein Capital Management LLC lifted its position in MediWound by 13.1% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 103,944 shares of the biopharmaceutical company’s stock worth $1,613,000 after buying an additional 12,060 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in MediWound by 14.8% during the first quarter. Bank of New York Mellon Corp now owns 18,357 shares of the biopharmaceutical company’s stock worth $285,000 after buying an additional 2,370 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Trading Down 0.2%

Shares of NASDAQ MDWD opened at $16.57 on Thursday. MediWound Ltd. has a twelve month low of $14.14 and a twelve month high of $22.50. The stock has a fifty day simple moving average of $18.85 and a 200-day simple moving average of $18.46. The stock has a market capitalization of $179.12 million, a PE ratio of -6.28 and a beta of 0.25.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.68). MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. The firm had revenue of $5.71 million during the quarter, compared to analyst estimates of $5.68 million. On average, equities analysts predict that MediWound Ltd. will post -2.66 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Zacks Research downgraded MediWound from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Oppenheimer began coverage on MediWound in a research report on Monday, June 2nd. They issued an “outperform” rating and a $34.00 target price on the stock. HC Wainwright set a $31.00 target price on MediWound and gave the company a “buy” rating in a research report on Thursday, May 22nd. Finally, Wall Street Zen downgraded MediWound from a “hold” rating to a “sell” rating in a research report on Friday, July 18th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.25.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.